Company Overview and News

 
Brain Resource targets cash boost ahead of product commercialisation

2017-10-23 proactiveinvestors.com.au
Brain Resource Ltd (ASX:BRC) has a very unique company strategy which includes commercialising its MyBrainSolutions and iSPOT products.
Upvote Downvote

 
Global Cognitive Assessment & Training Market By Component, By Assessment Type, By End User, By Region, Competition Forecast & Opportunities, 2012 - 2022

2017-08-17 prnewswire
NEW YORK, Aug. 17, 2017 /PRNewswire/ -- Global cognitive assessment & training market is projected to reach $9.48 billion by the end of 2022. Growth is expected to be driven by several factors including rising adoption of cognitive assessment & training tools across various sectors, such as healthcare, corporate and education; increasing technological advancements; growing awareness about brain fitness; coupled with rising aging population and increasing life expectancy across the globe.
Upvote Downvote

 
Global Cognitive Assessment and Training (Pen and Paper-based, Hosted, Biometrics) Market 2017-2021

2017-08-14 prnewswire
The "Cognitive Assessment and Training Market - Global Forecast to 2021" report has been added to Research and Markets' offering.
Upvote Downvote

 
Cognitive Assessment and Training Market by Assessment Type (Pen- and Paper-Based, Hosted, Biometrics), Component, Application (Clinical Trial, Screening & Diagnostics, Brain Training, Academic Research), Vertical, and Region - Global Forecast to 20

2017-04-12 prnewswire
NEW YORK, April 12, 2017 /PRNewswire/ -- Rapidly aging global population, increasing awareness about brain fitness, and advancements in technology are driving the cognitive assessment and training market The cognitive assessment and training market size is expected to grow from USD 1.98 billion in 2016 to USD 8.06 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 32.3% during the forecast period.
Upvote Downvote

 
Brain Resource gets ready to raise

2017-03-26 proactiveinvestors.com.au
Brain Resource (ASX:BRC) has been granted a trading halt by the ASX, pending details of a capital raising.
Upvote Downvote

 
Cognitive Assessment and Training in Healthcare Market by Assessment Type, Components, Application, & Region - Global forecast to 2021

2017-03-07 prnewswire
NEW YORK, March 6, 2017 /PRNewswire/ -- Aging global population, increasing awareness about brain fitness, and advancements in technology are driving the cognitive assessment and training in healthcare market" The market size of cognitive assessment and training in healthcare market is expected to grow from USD 962.0 million in 2016 to USD 4,127.2 million by 2021, at a Compound Annual Growth Rate (CAGR) of 33.
Upvote Downvote

 
R&D cash received

2016-04-22 asx.com.au
Upvote Downvote

 
Expanding Mindfulness Meditation to Include Brain Science Insights in an Elegant and Simple App

2016-04-20 prnewswire
SAN FRANCISCO, April 20, 2016 /PRNewswire/ -- To say you're busy is an understatement. You spend the majority of your waking hours at work or commuting, and a few precious ones with friends and family or keeping up your home and your life. But where are the minutes for yourself and your personal health and wellbeing? How do you maintain your energy, focus and perspective while minimizing the stress of it all?
Upvote Downvote

 
iSPOT Genetic Test

2016-03-30 asx.com.au
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...